SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Myogen (MYOG)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (17)2/14/2006 7:36:47 AM
From: kenhott  Read Replies (2) of 50
 
MYOG has been very smart in the design of their trials. Maybe it is luck the way it worked out but they did a good job fitting.

Of course I don't know how it will all play out at the end but the likely path is that docs will use 2.5mg, 5mg, and 10mg in the treatment of the disease. Having 3 effective dosages is a big deal in the management of this disease. It allows for titration, fitting the dose to the patient.

As you well know people are all different and one dose does not usually fit all.

10mg will likely bring higher liver issues. But what is the benefit? And the drug does not have to be labeled for 10mg for docs to use it given that it is in the phase 3. So if 10mg = 5mg in efficacy but higher LFT then no one would use 10mg. But that is not the likely outcome. The likely outcome is higher everything (less than 10% LFT) which would present docs with the opportunity to titrate up to 10mg for max benefit.

I still say don't believe yet that this product is not better in the field than ENCY's. Not yet.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News